Kyinno Biotechnology, a China‑based biotech company, announced the completion of its Series B financing round raising close to RMB 250 million. The round was co‑led by BioTrack Capital, the Beijing Medical and Health Industry Investment Fund, and E-Town Capital, with participation from China Everbright Limited (0165.HK), Jinyi Fuxin, Renai Capital, Yizhuang Investment, and existing shareholder Yuanhui Chuangyi, which increased its stake.
Transaction Details
Item
Details
Financing Round
Series B
Amount Raised
Close to RMB 250 million
Co‑Leads
BioTrack Capital, Beijing Medical and Health Industry Investment Fund, E-Town Capital
Accelerate collaborative development and clinical advancement of First‑in‑Class and Best‑in‑Class bispecific/multi‑specific antibodies
Technology Platforms
Strengthen proprietary “Common Light Chain” and “Nanobody” technology platforms
Global Expansion
Actively expand global business development partnerships
Technology Platforms
Platform
Description
Common Light Chain
Proprietary technology enabling efficient development of bispecific and multi‑specific antibodies
Nanobody
Platform for generating nanobody‑based therapeutic candidates
Strategic Implications
For Kyinno: The financing validates its bispecific antibody platform and provides capital to advance a differentiated pipeline toward clinical milestones and potential global partnerships.
For Investors: Co‑leads include government‑backed funds (Beijing Medical, E‑Town), signaling policy support for innovative biotech, while private investors gain exposure to the high‑growth bispecific therapy market.
For Market: China’s bispecific antibody sector is projected to reach ¥15 billion (≈ US$2.1 B) by 2030; Kyinno’s platform positions it as a competitive player in next‑generation immuno‑oncology and autoimmune therapies.
Forward‑Looking Statements This brief contains forward‑looking statements regarding Kyinno’s pipeline advancement, platform development, and global partnership expansion. Actual results may differ due to clinical risks, competitive dynamics, and market conditions.-Fineline Info & Tech
By Fineline Cube 